<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(3)</volume><submitter>Ricci Z</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1 receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).&lt;h4>Methods&lt;/h4>A prospective single-center randomized double-blind controlled trial was conducted in a pediatric cardiac surgery department. We randomized infants younger than 1 year with CHD and biventricular anatomy (with exclusion of isolated ventricular and atrial septal defect) to receive blindly a continuous infusion of fenoldopam at 1 μg/kg/min or placebo during CPB. Perioperative urinary and plasma levels of neutrophil gelatinase-associated lipocaline (NGAL), cystatin C (CysC), and creatinine were measured to assess renal injury after C</pubmed_abstract><journal>Critical care (London, England)</journal><pagination>R160</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3219034</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery.</pubmed_title><pmcid>PMC3219034</pmcid><pubmed_authors>Ricci Z</pubmed_authors><pubmed_authors>Muraca M</pubmed_authors><pubmed_authors>Cogo P</pubmed_authors><pubmed_authors>Favia I</pubmed_authors><pubmed_authors>Garisto C</pubmed_authors><pubmed_authors>Morelli S</pubmed_authors><pubmed_authors>Picardo S</pubmed_authors><pubmed_authors>Luciano R</pubmed_authors><pubmed_authors>Di Chiara L</pubmed_authors></additional><is_claimable>false</is_claimable><name>High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery.</name><description>&lt;h4>Introduction&lt;/h4>The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1 receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).&lt;h4>Methods&lt;/h4>A prospective single-center randomized double-blind controlled trial was conducted in a pediatric cardiac surgery department. We randomized infants younger than 1 year with CHD and biventricular anatomy (with exclusion of isolated ventricular and atrial septal defect) to receive blindly a continuous infusion of fenoldopam at 1 μg/kg/min or placebo during CPB. Perioperative urinary and plasma levels of neutrophil gelatinase-associated lipocaline (NGAL), cystatin C (CysC), and creatinine were measured to assess renal injury after C</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Jun</publication><modification>2025-04-21T14:11:39.685Z</modification><creation>2019-03-27T00:46:06Z</creation></dates><accession>S-EPMC3219034</accession><cross_references><pubmed>21714857</pubmed><doi>10.1186/cc10295</doi></cross_references></HashMap>